Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer

Massimiliano Pacilio; Miriam Conte; Viviana Frantellizzi; Maria Silvia De Feo; Antonio Rosario Pisani; Andrea Marongiu; Susanna Nuvoli; Giuseppe Rubini; Angela Spanu; Giuseppe De Vincentis

doi:10.3390/diagnostics12071763

journal article Open Access Jul 21, 2022

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer

Massimiliano Pacilio

Miriam Conte Viviana Frantellizzi

Maria Silvia De Feo Antonio Rosario Pisani Andrea Marongiu

Susanna Nuvoli

Giuseppe Rubini

Angela Spanu

Giuseppe De Vincentis

Diagnostics Vol. 12 No. 7 pp. 1763 · MDPI AG

View at Publisher Save 10.3390/diagnostics12071763

Abstract

The most frequent thyroid cancer is Differentiated Thyroid Cancer (DTC) representing more than 95% of cases. A suitable choice for the treatment of DTC is the systemic administration of 131-sodium or potassium iodide. It is an effective tool used for the irradiation of thyroid remnants, microscopic DTC, other nonresectable or incompletely resectable DTC, or all the cited purposes. Dosimetry represents a valid tool that permits a tailored therapy to be obtained, sparing healthy tissue and so minimizing potential damages to at-risk organs. Absorbed dose represents a reliable indicator of biological response due to its correlation to tissue irradiation effects. The present paper aims to focus attention on iodine therapy for DTC treatment and has developed due to the urgent need for standardization in procedures, since no unique approaches are available. This review aims to summarize new proposals for a dosimetry-based therapy and so explore new alternatives that could provide the possibility to achieve more tailored therapies, minimizing the possible side effects of radioiodine therapy for Differentiated Thyroid Cancer.

Topics

No keywords indexed for this article. Browse by subject →

References

166

[1]

Cabanillas "Thyroid cancer" Lancet (2016) 10.1016/s0140-6736(16)30172-6

[2]

Pacini "Italian consensus on diagnosis and treatment of differentiated thyroid cancer: Joint statements of six Italian societies" J. Endocrinol. Investig. (2018) 10.1007/s40618-018-0884-2

[3]

Luster "Guide-lines for radioiodine therapy of differentiated thyroid cancer" Eur. J. Nucl. Med. Mol. Imaging (2008) 10.1007/s00259-008-0883-1

[4]

Fariduddin, M.M., and Syed, W. (2022). Hurthle Cell Thyroid Carcinoma, StatPearls Publishing.

[5]

Luo "Hysterectomy, Oophorectomy, and Risk of Thyroid Cancer" J. Clin. Endocrinol. Metab. (2016) 10.1210/jc.2016-2011

[6]

Girotto "Risk Factors for Thyroid Cancer: What Do We Know So Far?" Acta Clin. Croat. (2020)

[7]

Duntas "Risk and prognostic factors for differentiated thyroid cancer" Hell. J. Nucl. Med. (2006)

[8]

Yoo, S.K., Lee, S., Kim, S.J., Jee, H.G., Kim, B.A., Cho, H., Song, Y.S., Cho, S.W., Won, J.K., and Shin, J.Y. (2016). Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. PLoS Genet., 12. 10.1371/journal.pgen.1006239

[9]

Ganly "Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Land-scapes" Cancer Cell (2018) 10.1016/j.ccell.2018.07.002

[10]

Landa "Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers" J. Clin. Investig. (2016) 10.1172/jci85271

[11]

Dinneen "Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades" J. Clin. Endocrinol. Metab. (1995)

[12]

Durante "Long-term outcome of 444 patients with distant metastases from papil-lary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy" J. Clin. Endocrinol. Metab. (2006) 10.1210/jc.2005-2838

[13]

Casara "Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognos-tic variables" J. Nucl. Med. (1993)

[14]

Mazzaferri "Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer" J. Clin. Endocrinol. Metab. (2001) 10.1210/jcem.86.4.7407

[15]

Corssmit "Survival and Death Causes in Differentiated Thyroid Carcinoma" J. Clin. Endocrinol. Metab. (2006) 10.1210/jc.2005-1322

[16]

Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). TNM Classification of Malignant Tumours, John Wiley & Sons. [8th ed.]. 10.1002/9780471420194.tnmc26.pub3

[17]

Tuttle "Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?" Thyroid (2017) 10.1089/thy.2017.0102

[18]

Sciuto "Natural history and clinical outcome of differentiated thyroid carcinoma: A retrospective analysis of 1503 patients treated at a single institution" Ann. Oncol. (2009) 10.1093/annonc/mdp050

[19]

Haugen "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer" Thyroid (2016) 10.1089/thy.2015.0020

[20]

Tuttle "Controversies, Consensus, and Collaboration in the Use of (131)I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medi-cine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association" Thyroid (2019) 10.1089/thy.2018.0597

[21]

Pelizzo "Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): A mono-institutional 12-year experience" Nucl. Med. Commun. (2004) 10.1097/01.mnm.0000126625.17166.36

[22]

Besic "The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid" Thyroid (2003) 10.1089/105072503322238845

[23]

Robbins "Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning" J. Clin. Endocrinol. Metab. (2006) 10.1210/jc.2005-1534

[24]

Sandeep "Second primary cancers in thyroid cancer patients: A multination-al record linkage study" J. Clin. Endocrinol. Metab. (2006) 10.1210/jc.2005-2009

[25]

Rubino "Second primary malignancies in thyroid cancer patients" Br. J. Cancer (2003) 10.1038/sj.bjc.6601319

[26]

Schlumberger "Leukaemias and cancers following iodine-131 administration for thyroid cancer" Br. J. Cancer (1997) 10.1038/bjc.1997.130

[27]

Hackshaw "131I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review" J. Clin. Endocrinol. Metab. (2007) 10.1210/jc.2006-1345

[28]

Sgouros "Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer" J. Nucl. Med. (2005)

[29]

Sgouros "Lung toxicity in radioiodine therapy of thyroid carcinoma: Development of a dose-rate method and dosimetric implications of the 80-mCi rule" J. Nucl. Med. (2006)

[30]

Song "Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases" J. Nucl. Med. (2006)

[31]

Ciarallo "Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update" Am. J. Roentgenol. (2020) 10.2214/ajr.19.22626

[32]

Atkins "Dosimetrically Determined Doses of Radioiodine for the Treatment of Metastatic Thyroid Carcinoma" Thyroid (2002) 10.1089/105072502753522356

[33]

Verburg "Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma" Q. J. Nucl. Med. Mol. Imaging (2019) 10.23736/s1824-4785.19.03196-0

[34]

Beierwaltes "The treatment of thyroid carcinoma with radioactive iodine" Semin. Nucl. Med. (1978) 10.1016/s0001-2998(78)80009-9

[35]

Schlumberger "Long-term results of treatment of 283 patients with lung and bone metastases from differen-tiated thyroid carcinoma" J. Clin. Endocrinol. Metab. (1986) 10.1210/jcem-63-4-960

[36]

Menzel "“High-dose” radio-iodine therapy in advanced differentiated thyroid carcinoma" J. Nucl. Med. (1996)

[37]

Iizuka "Comparison between the different doses of radioactive iodine abla-tion prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer" Ann. Nucl. Med. (2019) 10.1007/s12149-019-01357-6

[38]

Qu "Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: A preliminary clinical trial" Ann. Nucl. Med. (2017) 10.1007/s12149-016-1133-4

[39]

Ward "Cumulative doses of radioiodine in the treatment of differentiated thy-roid carcinoma: Knowing when to stop" Arq. Bras. Endocrinol. Metab. (2010) 10.1590/s0004-27302010000900006

[40]

"Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review" Endocr. Relat. Cancer (2005) 10.1677/erc.1.00880

[41]

Franzius "Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer" Nucl. Med. (2007)

[42]

Petrich "Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: Side-effects and influence of age" Eur. J. Pediatr. (2001)

[43]

Lange "Functioning pulmonary metastases of thyroid cancer: Does radioiodine influence the prognosis?" Eur. J. Nucl. Med. Mol. Imaging (2003) 10.1007/s00259-003-1174-5

[44]

Ylli "Conventional Radioiodine Therapy for Differentiated Thyroid Cancer" Endocrinol. Metab. Clin. North. Am. (2019) 10.1016/j.ecl.2018.11.005

[45]

Ghachem "A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer" Eur. Arch. Otorhinolaryngol. (2016) 10.1007/s00405-016-4111-5

[46]

Finessi "Major limits of dosimetrically determined activities in advanced differentiated thyroid carcinoma" Q. J. Nucl. Med. Mol. Imaging (2019) 10.23736/s1824-4785.19.03211-4

[47]

Andresen "Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity" Eur. Thyroid J. (2017) 10.1159/000468927

[48]

Benua "The relation of radioiodine dosimetry to results and com-plications in the treatment of metastatic thyroid cancer" Am. J. Roentgenol. Radium Ther. Nucl. Med. (1962)

[49]

Lassmann "EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: Blood and bone marrow dosimetry in differentiated thyroid cancer therapy" Eur. J. Nucl. Med. Mol. Imaging (2008) 10.1007/s00259-008-0761-x

[50]

Wang "Post-treatment surveillance of thyroid cancer" Eur. J. Surg. Oncol. (2017) 10.1016/j.ejso.2017.07.004

Showing 50 of 166 references

Cited By

22

Toward personalized iodine-131 therapy: A review of dosimetric strategies

Mostafa Jalilifar, Parham Geramifar · 2026

Applied Radiation and Isotopes

Metrics

22

Citations

166

References

Details

Published: Jul 21, 2022
Vol/Issue: 12(7)
Pages: 1763
License: View

Authors

M

Massimiliano Pacilio

Medical Physics Department, “Policlinico Umberto I” University Hospital, 00161 Rome, Italy

M

Miriam Conte

Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy

V

Viviana Frantellizzi

Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy

M

Maria Silvia De Feo

Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy

A

Antonio Rosario Pisani

Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy

A

Andrea Marongiu

Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy

S

Susanna Nuvoli

Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy

G

Giuseppe Rubini

Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy

A

Angela Spanu

Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy

G

Giuseppe De Vincentis

Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy

Cite This Article

Massimiliano Pacilio, Miriam Conte, Viviana Frantellizzi, et al. (2022). Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer. Diagnostics, 12(7), 1763. https://doi.org/10.3390/diagnostics12071763

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer

You May Also Like